Risk of Adverse Pregnancy Outcomes in Women with Polycystic Ovary Syndrome: Population Based Cohort Study

Overview

Journal BMJ

Specialty General Medicine

Date 2011 Oct 15

PMID 21998337

Citations 88

Authors

Nathalie Roos

Helle Kieler

Lena Sahlin

Gunvor Ekman-Ordeberg

Henrik Falconer

Olof Stephansson

Affiliations

Soon will be listed here.

Abstract

Objective: To study the risk of adverse pregnancy outcomes in women with polycystic ovary syndrome, taking into account maternal characteristics and assisted reproductive technology.

Design: Population based cohort study.

Setting: Singleton births registered in the Swedish medical birth register between 1995 and 2007.

Participants: By linkage with the Swedish patient register, 3787 births among women with a diagnosis of polycystic ovary syndrome and 1,191,336 births among women without such a diagnosis.

Main Outcome Measures: Risk of adverse pregnancy outcomes (gestational diabetes, pre-eclampsia, preterm birth, stillbirth, neonatal death, low Apgar score (<7 at five minutes), meconium aspiration, large for gestational age, macrosomia, small for gestational age), adjusted for maternal characteristics (body mass index, age), socioeconomic factors (educational level, and cohabitating with infant's father), and assisted reproductive technology.

Results: Women with polycystic ovary syndrome were more often obese and more commonly used assisted reproductive technology than women without such a diagnosis (60.6% v 34.8% and 13.7% v 1.5%). Polycystic ovary syndrome was strongly associated with pre-eclampsia (adjusted odds ratio 1.45, 95% confidence interval 1.24 to 1.69) and very preterm birth (2.21, 1.69 to 2.90) and the risk of gestational diabetes was more than doubled (2.32, 1.88 to 2.88). Infants born to mothers with polycystic ovary syndrome were more prone to be large for gestational age (1.39, 1.19 to 1.62) and were at increased risk of meconium aspiration (2.02, 1.13 to 3.61) and having a low Apgar score (<7) at five minutes (1.41, 1.09 to 1.83).

Conclusions: Women with polycystic ovary syndrome are at increased risk of adverse pregnancy and birth outcomes that cannot be explained by assisted reproductive technology. These women may need increased surveillance during pregnancy and parturition.

Citing Articles

Atlas of genetic and phenotypic associations across 42 female reproductive health diagnoses.

Pujol Gualdo N, Dzigurski J, Rukins V, Pajuste F, Wolford B, Vosa M Nat Med. 2025; .

PMID: 40069456 DOI: 10.1038/s41591-025-03543-8.

Maternal polycystic ovary syndrome and Offspring's Risk of Cardiovascular diseases in Childhood and Young Adulthood.

Yang F, Wang Z, Sorensen H, Janszky I, Gissler M, Yuan W Nat Commun. 2024; 15(1):10414.

PMID: 39614085 PMC: 11607077. DOI: 10.1038/s41467-024-54795-w.

Predicting Unfavorable Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS) Patients Using Machine Learning Algorithms.

Mogos R, Gheorghe L, Carauleanu A, Vasilache I, Munteanu I, Mogos S Medicina (Kaunas). 2024; 60(8).

PMID: 39202579 PMC: 11356493. DOI: 10.3390/medicina60081298.

Pregnancies through oocyte donation. A mini review of pathways involved in placental dysfunction.

Caradeux J, Fernandez B, Avila F, Valenzuela A, Mondion M, Figueras F Front Med (Lausanne). 2024; 11:1338516.

PMID: 38298815 PMC: 10827872. DOI: 10.3389/fmed.2024.1338516.

Metabolic hormones are integral regulators of female reproductive health and function.

Athar F, Karmani M, Templeman N Biosci Rep. 2023; 44(1).

PMID: 38131197 PMC: 10830447. DOI: 10.1042/BSR20231916.

References

Sheiner E, Levy A, Menes T, Silverberg D, Katz M, Mazor M . Maternal obesity as an independent risk factor for caesarean delivery. Paediatr Perinat Epidemiol. 2004; 18(3):196-201. DOI: 10.1111/j.1365-3016.2004.00557.x. View

Fridstrom M, Nisell H, Sjoblom P, Hillensjo T . Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia?. Hypertens Pregnancy. 1999; 18(1):73-80. DOI: 10.3109/10641959909009612. View

Cnattingius S, Bergstrom R, Lipworth L, Kramer M . Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med. 1998; 338(3):147-52. DOI: 10.1056/NEJM199801153380302. View

Schieve L, Meikle S, Ferre C, Peterson H, Jeng G, Wilcox L . Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med. 2002; 346(10):731-7. DOI: 10.1056/NEJMoa010806. View

Jackson R, Gibson K, Wu Y, Croughan M . Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol. 2004; 103(3):551-63. DOI: 10.1097/01.AOG.0000114989.84822.51. View

Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9):3078-82. DOI: 10.1210/jcem.83.9.5090. View

Cok T, Tarim E, Bagis T . Isolated abnormal value during the 3-hour glucose tolerance test: which value is associated with macrosomia?. J Matern Fetal Neonatal Med. 2011; 24(8):1039-41. DOI: 10.3109/14767058.2010.545910. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

Vanky E, Salvesen K, Heimstad R, Fougner K, Romundstad P, Carlsen S . Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004; 19(8):1734-40. DOI: 10.1093/humrep/deh347. View

10.

Archer J, Chang R . Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5):737-54. DOI: 10.1016/j.bpobgyn.2004.05.007. View

11.

Asuncion M, Calvo R, San Millan J, Sancho J, Avila S, Escobar-Morreale H . A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85(7):2434-8. DOI: 10.1210/jcem.85.7.6682. View

12.

Kallen B, Finnstrom O, Nygren K, Olausson P, Wennerholm U . In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG. 2005; 112(11):1529-35. DOI: 10.1111/j.1471-0528.2005.00745.x. View

13.

Mikola M, Hiilesmaa V, Halttunen M, SUHONEN L, Tiitinen A . Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001; 16(2):226-9. DOI: 10.1093/humrep/16.2.226. View

14.

Baeten J, Bukusi E, Lambe M . Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health. 2001; 91(3):436-40. PMC: 1446581. DOI: 10.2105/ajph.91.3.436. View

15.

Salvesen K, Vanky E, Carlsen S . Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation?. Ultrasound Obstet Gynecol. 2007; 29(4):433-7. DOI: 10.1002/uog.3965. View

16.

Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-67. PMC: 2773709. DOI: 10.1007/s10654-009-9350-y. View

17.

Rajashekar L, Krishna D, Patil M . Polycystic ovaries and infertility: Our experience. J Hum Reprod Sci. 2009; 1(2):65-72. PMC: 2700664. DOI: 10.4103/0974-1208.44113. View

18.

Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J . Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003; 18(7):1438-41. DOI: 10.1093/humrep/deg289. View

19.

Radon P, McMahon M, Meyer W . Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol. 1999; 94(2):194-7. DOI: 10.1016/s0029-7844(99)00252-5. View

20.

Troisi R, Potischman N, Johnson C, Roberts J, Lykins D, Harger G . Estrogen and androgen concentrations are not lower in the umbilical cord serum of pre-eclamptic pregnancies. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 Pt 1):1268-70. View